Cambridge Investment Research Advisors Inc. Makes New Investment in CalciMedica Inc. (NASDAQ:CALC)

Cambridge Investment Research Advisors Inc. bought a new position in shares of CalciMedica Inc. (NASDAQ:CALC) during the first quarter, HoldingsChannel.com reports. The firm bought 23,539 shares of the company’s stock, valued at approximately $45,000.

Other hedge funds also recently added to or reduced their stakes in the company. 180 Wealth Advisors LLC acquired a new stake in CalciMedica during the 1st quarter worth approximately $31,000. Cetera Investment Advisers lifted its holdings in CalciMedica by 37.1% during the 4th quarter. Cetera Investment Advisers now owns 16,873 shares of the company’s stock worth $60,000 after buying an additional 4,566 shares in the last quarter. Wealthedge Investment Advisors LLC acquired a new stake in shares of CalciMedica in the 4th quarter valued at $98,000. Atria Investments Inc raised its holdings in shares of CalciMedica by 28.3% in the 4th quarter. Atria Investments Inc now owns 34,012 shares of the company’s stock valued at $120,000 after purchasing an additional 7,509 shares in the last quarter. Finally, Corient Private Wealth LLC acquired a new stake in shares of CalciMedica in the 4th quarter valued at $135,000.

CalciMedica Price Performance

Shares of CALC opened at $2.05 on Wednesday. CalciMedica Inc. has a twelve month low of $1.42 and a twelve month high of $5.97. The firm’s fifty day simple moving average is $1.75 and its 200-day simple moving average is $2.10. The firm has a market capitalization of $28.64 million, a price-to-earnings ratio of -1.31 and a beta of 1.24. The company has a current ratio of 5.66, a quick ratio of 5.66 and a debt-to-equity ratio of 0.79.

CalciMedica (NASDAQ:CALC) last announced its quarterly earnings data on Wednesday, May 14th. The company reported ($0.36) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.07. Equities analysts forecast that CalciMedica Inc. will post -2.21 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and issued a $16.00 price objective on shares of CalciMedica in a report on Thursday, May 15th.

CalciMedica Profile

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.